5 results about "Isoniazid" patented technology

The invention discloses a preparation method and application of a BCG (Bacillus Calmette Guerin)-modified polydopamine targeted macrophage nano-system loaded with isoniazide and Mn < 2 + >, and belongs to the technical field of biomedicine. The invention discloses a preparation method of a BCG (bacillus calmette-guerin vaccine) modified polydopamine targeted macrophage nano system loaded with isoniazide and Mn < 2 + >. The preparation method comprises the following steps: preparing MPDA NPs, INH / Mn < 2 + > MPDA NPs and BCG INH / Mn < 2 + > MPDA NPs. According to the invention, a macrophage-targeted BCG modified MPDA NPs drug loading system is used for loading INH and Mn < 2 + >, Mycobacterium tuberculosis (Mtb) is directly killed by INH, a cGAS-STING autophagy pathway is efficiently activated in cooperation with Mn < 2 + > to promote lysosome to digest Mtb phagosome, the problem of immune escape of Mtb is solved, and a theoretical and experimental foundation is laid for developing a new host-oriented tuberculosis treatment technology.

This invention aims to solve the problems of poor flowability of existing nicotinamide mononucleotide (NMN) single material, leading to poor flowability, uneven mixing, and poor content uniformity in NMN formulation preparation. It provides a safe and highly flowable nicotinamide mononucleotide-proline co-crystal. This co-crystal exhibits diffraction peaks at 5.5±0.2° and 16.8±0.2° using Cu-Ka radiation and X-ray powder diffraction at 2θ angles. This co-crystal possesses good bulk density and flowability, allowing for direct tableting or capsule filling of the powder. The product weight variation meets pharmacopoeia requirements, and the process is simple, making it suitable for commercial production. Furthermore, proline, a natural amino acid and a component of collagen, is safer and more reliable as a co-crystal form than isoniazid (classified as a Group 3 carcinogen by the WHO), which is disclosed in existing technologies.

The invention belongs to the field of biological medicine, and particularly relates to application of murrayone or a pharmaceutically acceptable carrier or excipient thereof in preparation of a medicine for preventing and / or treating mycobacterium tuberculosis infection. In-vitro experiments show that murrayone has specific and efficient inhibiting and killing effects on mycobacterium tuberculosis, and has no activity on common gram-positive and gram-negative bacteria. When the murrayone is combined with first-line antituberculosis drugs (such as isoniazide and rifampicin), the drug effects are added. A time killing curve proves that the mycobacterium tuberculosis with high bacterial loading capacity can be completely removed within 48 hours, and the sterilizing effect is lasting. Cell experiments show that the compound has low toxicity to THP-1 human macrophages and good safety, and can effectively kill intracellular infected mycobacterium tuberculosis clinical strains. Therefore, the murrayone can be used as a single drug component or a drug combination component, is used for developing novel, efficient and safe antituberculosis drugs, and is particularly suitable for treating infectious diseases caused by mycobacterium tuberculosis.

The invention relates to an isoniazide injection and a preparation method thereof, every 1000 ml of the isoniazide injection contains 50 g of isoniazide, anhydrous disodium hydrogen phosphate and methionine, every 1000 ml of the isoniazide injection contains 3.5-4.0 g of anhydrous disodium hydrogen phosphate and 10.2-12.6 g of methionine, so that the isoniazide injection has good stability, the preparation method is simple, and the isoniazide injection is suitable for industrial production. And complicated processes such as nitrogen charging and oxygen content control are not needed.

The application discloses a high performance liquid chromatography-tandem mass spectrometry method for detecting the concentration of isoniazid in human cerebrospinal fluid, and belongs to the technical field of analytical chemistry and clinical therapeutic drug monitoring. The method comprises the following steps: short column and rapid gradient elution are adopted to realize chromatographic separation within 3.5 minutes; isoniazid and a deuterium internal standard thereof are specifically detected in a multiple reaction monitoring mode by optimizing mass spectrometry parameters; and sample pretreatment is performed by using one-step acetonitrile precipitation. Verification shows that the lower limit of quantification of the method reaches 5 ng / mL, the linear range is 5-4000 ng / mL, and the precision, accuracy and stability all meet the standards. The application has the advantages of ultrahigh sensitivity, rapid analysis, simple operation and strong anti-interference capability, and provides a precise and reliable drug concentration monitoring tool for individualized treatment of patients with tubercular meningitis.